S5 - E6.4 - Finding The MASH Patients That Are The Initial Rezdiffra Targets
Send us a text One pivotal question surrounding the launch of Rezdiffra is "Which MASH patients are the correct targets for the first MASH drug?" This conversation focuses on the tools and education the health system will need to locate these patients and have them treated by the appropriate prescribers. The conversation starts by considering educational goals. Zobair Younossi asks what is practical and proceeds to answer his own question. He starts by pointing out that mos...
19 Maalis 202412min
S5 - E6.3 - Staging and screening patients for Rezdiffra using NITs
Send us a text This conversation focuses on the necessity of using NITs to screen and identify Rezdiffra patients, while at the same time acknowledging the shortcomings of current tests. Panelists suggest some different NIT testing strategies while commenting on upsides and potential challenges for each MASH NIT. Laurent Castera joins the conversation at the beginning, which is helpful given his extensive research and knowledge of the surrounding communities. Laurent points out that distingu...
18 Maalis 202415min
S5 - E6.2 - How Approval Of Rezdiffra,The First MASH Drug, Might Improve Patient Adherence To Lifestyle Recommendations
Send us a text This conversation focuses on what panelists see as a key (and somewhat unusual) benefit of Rezdiffra: that having a prescription drug for MASH creates a better environment for discussing lifestyle intervention and improving overall patient adherence with diet and exercise. This conversation focuses on the impact of having a drug on getting patients to comply with lifestyle interventions. Zobair Younossi starts by noting that, historically, it has been "very difficu...
18 Maalis 202411min
S5 - E6.1 - Rezdiffra Is Approved! How Key Opinion Leaders Processed The News About The First MASH Drug
Send us a text FDA approval of the first MASH drug, Rezdiffra, on March 14 marked what co-host and Key Opinion Leader Jörn Schattenberg describes as a "watershed moment" for hepatology. This opening discussion covers how panelists heard the news of Rezdiffra's approval, how they reacted, and their initial thoughts about appropriate patient targets. As the conversation starts, the various panelists describe their moves throughout the day on March 14th and their reactions when word of the FDA'...
18 Maalis 202411min
S5 - E6 - Rezdiffra Is Here! Key Opinion Leaders React To The First MASH Drug Approval
Send us a text Last Thursday, March 14, Rezdiffra (resmetirom) became the first MASH drug approved in the US. A global panel of Key Opinion Leaders convenes to discuss their excitement about this approval, the opportunities it will create and some of the (largely manageable) challenges it might present. 00:00:00 - Surf's Up: Season 5 Episode 6 Opening introduction from an excited, enthusiastic panel, including brief quotes taken directly from the episode discussion. 00:05:02 - Groundbreak...
16 Maalis 20241h 4min
S5 - E5.6 - From The Vault: Tsunami's First Look At MASEF, A Major New NIT
Send us a text This conversation comes from our first look at MASEF, last September, when lead author Mazen Noureddin joined the Surfers to discuss his recent breakthrough paper on this new NIT. The original conversation had a robust write-up: Mazen Noureddin joins co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to discuss serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). In late July, Mazen co-authored a paper on th...
10 Maalis 202413min
S5 - E5.5 - More on GLP-1s and a Broader MASH Wrap-up
Send us a text After some final discussion about GLP-1s, this conversation entails Roger Green summarizing what he has heard in the episode so far and testing for confirmation or correction. It goes fast and covers significant ground. Naim Alkhouri starts this conversation by discussing patients for whom he would prescribe resmetirom vs. GLP-1s. Lean MASH patients are likely to receive resmetirom. Earlier fibrosis patients are more likely to receive semaglutide. A multimorbid F3 patien...
10 Maalis 202411min
S5 - E5.4 - The dance of drug pricing and patient targets in MASH, PLUS: the role of GLP-1s
Send us a text This conversation touches on two important subjects: the impact of different potential resmetirom prices on the size and structure of the treatable MASH population, and the impact GLP-1s are having (and will have) on clinical trial recruitment and basic patient treatment. It starts with Naim Alkhouri expressing concern over the $39-52K price he has heard for resmetirom, which ICER has deemed cost-effective. He mentions another paper that says a price of $19,000 would be ...
10 Maalis 202411min
